Developer docs
API playgroundTry for free, no card

Search company profiles

Nosopharm

Full company profile

uuid0003igy

Namestring
Nosopharm
Websiteurl
nosopharm.com
Company typeenum
Private
Founded yearint
2009
Descriptiontext

Nosopharm is a French biotechnology company founded in 2009 and headquartered in Nîmes, France, focused on the research and development of anti-infective drugs. The firm operates as a small, privately-held R&D-stage organization with between one and ten employees, working in the pre-clinical or early-stage anti-infective drug discovery space. To date, Nosopharm has raised approximately $5 million across three equity rounds between 2013 and 2018 from French life-sciences investors including Bpifrance, Alto Invest, Auriga Partners, and KREAXI, a funding profile consistent with an early-stage European biotech sustaining an ongoing R&D program. The company has not disclosed pricing, products, or commercial revenue mechanics, consistent with a pre-clinical status, and its go-to-market model is implicitly the typical biotech path of internal discovery followed by out-licensing or partnership with larger pharmaceutical companies once candidates advance.

A material data-quality flag: the company's registered web domain (nosopharm.com) currently serves Indonesian-language affiliate content about online gambling platforms (casino, slots, lottery/togel, sports betting), which is unrelated to anti-infective drug R&D. This discrepancy most likely reflects domain repurposing, parking, or unauthorized scraping rather than a legitimate business pivot by the biotech. Investors should independently verify domain control, brand protection, and any reputational or cybersecurity exposure before any transaction.

The leadership team comprises co-founder and CSO Maxime Gualtieri and co-founder and CEO Philippe Villain-Guillot, consistent with a scientific founder profile typical of a French academic-spinout biotech. No management hires, board changes, or other post-2018 corporate actions are disclosed in the available data.

Short descriptiontext

Nosopharm is a French anti-infective drug R&D biotech founded in 2009 in Nîmes, operating with 1–10 employees and approximately $5 million in cumulative early-stage equity funding from French life-sciences investors.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersLyon, France
HQ citystring
Lyon
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Keyword5 values
anti-infective drugs, novel antibiotics, antimicrobial resistance, biopharmaceutical R&D, natural product discovery
Industry3 codes
PRIMARYHLAIAAAG
Infectious Disease & Antimicrobials Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAAAFAG
Microbiome Modulating Small Molecules & Antibiotic Alternatives
SECONDARYHLAAAFAD
Engineered Microbial Therapeutics (synthetic biology, gene circuits)
NAICS code3 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Biological Product (except Diagnostic) Manufacturing325414
  • Scientific Research and Development Services5417
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Services-Commercial Physical & Biological Research8731
Product category
Anti-infective Therapeutics
Social media profiles1 record
Marketing channels1 record

Each record includes

Title, Type, Stage, Description, Source

Cost components3 values
Personnel, Technology or R&D, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Nosopharm is a French biotechnology company founded in 2009 that researches and develops novel anti-infective drugs. Its work focuses on discovering new antibiotic compounds, exploiting biodiversity from uncultured microorganisms to address the growing problem of antimicrobial resistance.

Differentiator
Functional benefit
Problem solved
Product and service1 record
1Anti-infective drug candidates (R&D pipeline)
CategoryAnti-infective Therapeutics
Description

Pre-clinical and discovery-stage anti-infective drug candidates being developed by Nosopharm to address bacterial infections and antimicrobial resistance. Intended for future out-licensing or partnering with pharmaceutical companies.

Recent move3 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight1 record

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

French anti-infective biotech developing novel antibiotics against WHO priority pathogens; geographically and thematically the closest comparable to Nosopharm as a France-based, privately funded preclinical anti-infective discovery company.

TypeDirect peer
Description

France-headquartered biotech discovering novel antibacterial compounds; same stage, geography, and therapeutic focus as Nosopharm and a natural peer for partnership and funding competition.

TypeDirect peer
Description

Clinical-stage anti-infective company developing novel antibiotics for multi-drug resistant infections; comparable therapeutic mission, though at a more advanced clinical stage than Nosopharm.

4Nabriva Therapeutics
TypeDirect peer
Description

Specialty anti-infective company focused on pleuromutilin antibiotics; directly comparable as a developer of new chemical-class antibiotics targeting resistant pathogens.

TypeDirect peer
Description

Clinical-stage anti-infective biotech developing novel antimicrobial agents including Cloudbreak antiviral-antibody conjugates; comparable anti-infective innovator model.

TypeEmerging player
Description

Microbiome-derived therapeutics company developing defined bacterial consortia for infectious and immune-mediated diseases; comparable as a microbe-sourced drug discovery platform relevant to Nosopharm's anti-infective pipeline.

TypeBroad incumbent
Description

Commercial-stage anti-infective company (tetracycline class), an established player in the novel antibiotic space demonstrating both the regulatory pathway and commercial challenges typical for this category.

TypeBroad incumbent
Description

Large CRO/drug-discovery platform with an active anti-infectives unit and multiple partnerships in AMR; a relevant incumbent comparator for discovery-stage anti-infective platforms.

TypeBroad incumbent
Description

Swiss pharma company with an established anti-infective franchise and active investment in novel antibiotic R&D; relevant as a strategic partner / acquirer profile for an early French anti-infective biotech.

TypeOthers
Description

Not-for-profit R&D organization funding and partnering with antibiotic developers to address AMR; relevant ecosystem participant Nosopharm could engage for non-dilutive funding and late-stage development.

Market position
Strengths3 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat2 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights4 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Nosopharm

Anti-infective Therapeuticsnosopharm.com

Nosopharm is a French anti-infective drug R&D biotech founded in 2009 in Nîmes, operating with 1–10 employees and approximately $5 million in cumulative early-stage equity funding from French life-sciences investors.

What Nosopharm does

Nosopharm is a French biotechnology company founded in 2009 and headquartered in Nîmes, France, focused on the research and development of anti-infective drugs. The firm operates as a small, privately-held R&D-stage organization with between one and ten employees, working in the pre-clinical or early-stage anti-infective drug discovery space. To date, Nosopharm has raised approximately $5 million across three equity rounds between 2013 and 2018 from French life-sciences investors including Bpifrance, Alto Invest, Auriga Partners, and KREAXI, a funding profile consistent with an early-stage European biotech sustaining an ongoing R&D program. The company has not disclosed pricing, products, or commercial revenue mechanics, consistent with a pre-clinical status, and its go-to-market model is implicitly the typical biotech path of internal discovery followed by out-licensing or partnership with larger pharmaceutical companies once candidates advance.

A material data-quality flag: the company's registered web domain (nosopharm.com) currently serves Indonesian-language affiliate content about online gambling platforms (casino, slots, lottery/togel, sports betting), which is unrelated to anti-infective drug R&D. This discrepancy most likely reflects domain repurposing, parking, or unauthorized scraping rather than a legitimate business pivot by the biotech. Investors should independently verify domain control, brand protection, and any reputational or cybersecurity exposure before any transaction.

The leadership team comprises co-founder and CSO Maxime Gualtieri and co-founder and CEO Philippe Villain-Guillot, consistent with a scientific founder profile typical of a French academic-spinout biotech. No management hires, board changes, or other post-2018 corporate actions are disclosed in the available data.

Nosopharm firmographics

Firmographics
Name
Nosopharm
Website
https://nosopharm.com
Company type
Private
Founded year
2009
Operating status
Operating
Headcount range
1–10 employees
Short description
Nosopharm is a French anti-infective drug R&D biotech founded in 2009 in Nîmes, operating with 1–10 employees and approximately $5 million in cumulative early-stage equity funding from French life-sciences investors.
Ownership category
akta.pro rank

Nosopharm industry classification

Industry
Product category
Anti-infective Therapeutics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414), Scientific Research and Development Services (5417)
SIC
Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAIAAAG
Infectious Disease & Antimicrobials Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAAAFAG
Microbiome Modulating Small Molecules & Antibiotic Alternatives
SECONDARYHLAAAFAD
Engineered Microbial Therapeutics (synthetic biology, gene circuits)

Keywords

  • Anti-infective drugs
  • Novel antibiotics
  • Antimicrobial resistance
  • Biopharmaceutical R&D
  • Natural product discovery

Where Nosopharm is headquartered

Location

Headquarters

HQ city
Lyon
HQ country
France
HQ region
Europe

Markets served

Nosopharm business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations

Marketing channels1 record

Nosopharm product offering

Product offering

Core offering

Nosopharm is a French biotechnology company founded in 2009 that researches and develops novel anti-infective drugs. Its work focuses on discovering new antibiotic compounds, exploiting biodiversity from uncultured microorganisms to address the growing problem of antimicrobial resistance.

Differentiator

Problem solved

Functional benefit

Products and services

  • Anti-infective drug candidates (R&D pipeline) Pre-clinical and discovery-stage anti-infective drug candidates being developed by Nosopharm to address bacterial infections and antimicrobial resistance. Intended for future out-licensing or partnering with pharmaceutical companies.

Companies that use Nosopharm

Customer profile

Ideal customer profiles1 record

Nosopharm technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Nosopharm partnerships and signals

Strategic signal

Recent moves3 records

Expansion highlights1 record

Nosopharm competitors and assessment

Company assessment

Direct peers

  • Antabio: French anti-infective biotech developing novel antibiotics against WHO priority pathogens; geographically and thematically the closest comparable to Nosopharm as a France-based, privately funded preclinical anti-infective discovery company.
  • Mutabilis: France-headquartered biotech discovering novel antibacterial compounds; same stage, geography, and therapeutic focus as Nosopharm and a natural peer for partnership and funding competition.
  • Iterum Therapeutics: Clinical-stage anti-infective company developing novel antibiotics for multi-drug resistant infections; comparable therapeutic mission, though at a more advanced clinical stage than Nosopharm.
  • Nabriva Therapeutics: Specialty anti-infective company focused on pleuromutilin antibiotics; directly comparable as a developer of new chemical-class antibiotics targeting resistant pathogens.
  • Cidara Therapeutics: Clinical-stage anti-infective biotech developing novel antimicrobial agents including Cloudbreak antiviral-antibody conjugates; comparable anti-infective innovator model.

Emerging players

  • Vedanta Biosciences: Microbiome-derived therapeutics company developing defined bacterial consortia for infectious and immune-mediated diseases; comparable as a microbe-sourced drug discovery platform relevant to Nosopharm's anti-infective pipeline.

Broad incumbents

  • Paratek Pharmaceuticals: Commercial-stage anti-infective company (tetracycline class), an established player in the novel antibiotic space demonstrating both the regulatory pathway and commercial challenges typical for this category.
  • Evotec (Anti-infectives platform): Large CRO/drug-discovery platform with an active anti-infectives unit and multiple partnerships in AMR; a relevant incumbent comparator for discovery-stage anti-infective platforms.
  • Debiopharm: Swiss pharma company with an established anti-infective franchise and active investment in novel antibiotic R&D; relevant as a strategic partner / acquirer profile for an early French anti-infective biotech.

Others

  • GARDP (Global Antibiotic R&D Partnership): Not-for-profit R&D organization funding and partnering with antibiotic developers to address AMR; relevant ecosystem participant Nosopharm could engage for non-dilutive funding and late-stage development.

Market position

Strengths3 records

Weaknesses4 records

Competitive moat2 records

Key risks5 records

Key highlights4 records

Customer concentration

Nosopharm social profiles

Digital presence

Nosopharm financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Nosopharm leadership team

Management profile

Number of profiles

Profiles2 records

Nosopharm funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Nosopharm M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Nosopharm

What does Nosopharm do?

Nosopharm is a French biotechnology company founded in 2009 that researches and develops novel anti-infective drugs. Its work focuses on discovering new antibiotic compounds, exploiting biodiversity from uncultured microorganisms to address the growing problem of antimicrobial resistance.

Is Nosopharm a public or private company?

Nosopharm is a private company. It is classified as venture growth investor backed and is currently operating.

When was Nosopharm founded?

Nosopharm was founded in 2009. It employs 1 to 10 people.

Where is Nosopharm based?

Nosopharm is headquartered in Lyon, France, in the Europe region.

Who are Nosopharm's main competitors?

Direct peers on record are Antabio, Mutabilis, Iterum Therapeutics, Nabriva Therapeutics and Cidara Therapeutics. Vedanta Biosciences is listed as an emerging player. Broad incumbents are Paratek Pharmaceuticals, Evotec (Anti-infectives platform) and Debiopharm. GARDP (Global Antibiotic R&D Partnership) is listed as an others.

Does Nosopharm have an API?

No public API is recorded for Nosopharm.

What industry is Nosopharm in?

Nosopharm's product category is Anti-infective Therapeutics. Its primary akta.pro industry code is HLAIAAAG, Infectious Disease & Antimicrobials Pharmaceuticals, with a secondary code of HLAAAFAG, Microbiome Modulating Small Molecules & Antibiotic Alternatives. Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireGlobal $51.5 Billion Antibiotics Markets to 2028: Collaboration Between Pharma Companies is Boosting Industry GrowthResearchAndMarkets published a report projecting the global antibiotics market to reach USD 51.5 billion by 2028, driven by increasing collaboration between pharmaceutical companies to develop new antimicrobial therapies. The report highlights specific partnerships including Nosopharm with Evotec to develop NOSO-502, Forge Therapeutics with Basilea Pharma, and the Global Antibiotic Research and Development Partnership (GARDP) with Evotec, all focused on combating drug-resistant bacteria. In July 2020, a coalition of over a dozen pharma companies launched the AMR Action Fund with over USD 1 billion to support clinical research for new antibiotics targeting life-threatening infections.FinSMEsNosopharm Receives €1M Loan from BpifranceNosopharm, a Lyon-based biotech, received €1M in interest-free loan funding from Bpifrance. The company will use the funds for CMC development and regulatory preclinical research on its drug candidate NOSO-502, aiming to submit a clinical trial authorization in 2019 and begin first-in-human trials in 2020.FinSMEsNosopharm Raises €2.4M in FundingNosopharm, a French biotech firm, raised €2.4M from Auriga Partners, Kreaxi, and Alto Invest. The funds will accelerate preclinical development of its antibiotic NOSO-95179, targeting Enterobacteriaceae, with first-in-man studies expected in 2019.